NIVEGU.KNOW BEFORE YOU FLY

THE WORLD OF AVIATION.
YOUR JOURNEY, EXPLAINED.

Search Plan my trip
NASDAQ / LIVE COMPANY INTELLIGENCE

Altimmune, Inc.

Nasdaq-listed company. Follow earnings, filings, products, capital and the competitive forces moving the company.

TICKERALT
CORENasdaq-listed company
WATCHEarnings + filings + operating news
STATUSContinuously updated
LIVE / ALT COVERAGE

What’s moving Altimmune, Inc. now

Current reporting with the operating signal separated from the noise.

01
Altimmune, Inc: Altimmune Announces Second Quarter 2026 Financial Results and Business Update

Altimmune, Inc: Altimmune Announces Second Quarter 2026 Financial Results and Business Update

The story matters when it changes Altimmune, Inc.’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
02
Altimmune, Inc. (ALT) Gains Analyst Support as Pemvidutide Advances

Altimmune, Inc. (ALT) Gains Analyst Support as Pemvidutide Advances

The development tests whether Altimmune, Inc. can turn product investment into adoption, revenue and durable advantage.

Watch next: confirmation in a company filing, official release or regulator record.
03
Altimmune, Inc. Enrolls First Subject in Phase 2 RECLAIM Trial for Pemvidutide in Alcohol Use Disorder

Altimmune, Inc. Enrolls First Subject in Phase 2 RECLAIM Trial for Pemvidutide in Alcohol Use Disorder

The development tests whether Altimmune, Inc. can turn product investment into adoption, revenue and durable advantage.

Watch next: confirmation in a company filing, official release or regulator record.
04
Altimmune, Inc. Announces Virtual R&D Day Focused on Pemvidutide Development and Upcoming Trial Data

Altimmune, Inc. Announces Virtual R&D Day Focused on Pemvidutide Development and Upcoming Trial Data

The story matters when it changes Altimmune, Inc.’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
05
With 56% institutional ownership, Altimmune, Inc. (NASDAQ:ALT) is a favorite amongst the big guns

With 56% institutional ownership, Altimmune, Inc. (NASDAQ:ALT) is a favorite amongst the big guns

The story matters when it changes Altimmune, Inc.’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
06
Altimmune, Inc. (ALT) Q3 2024 Earnings Call Transcript

Altimmune, Inc. (ALT) Q3 2024 Earnings Call Transcript

Investors are testing whether Altimmune, Inc.’s operating performance supports its strategy and valuation.

Watch next: the filing, cash flow, guidance and capital-expenditure plan.
PRIMARY DOCUMENTS / SEC EDGAR

Latest ALT filings.

Investor-relevant reports are shown first, followed by the company’s other recent official submissions.

SEC feed temporarily unavailable

No verified filing is shown until the official endpoint responds.

EARNINGS / QUARTERLY TRACKER

Altimmune, Inc., quarter by quarter.

Results, guidance and earnings coverage are grouped only when the source headline identifies the reporting period.